GBS trivalent vaccine

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Bacterial Infection Due to Streptococcus, Group BGBS DiseaseStreptococcus Agalactiae

Phase 2

Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women

CompletedNCT02046148

GlaxoSmithKlineGBS Disease, Streptococcus Agalactiae

Start: 2014-03-18End: 2016-03-26Updated: 2020-12-29

Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.

CompletedNCT02690181

GlaxoSmithKlineBacterial Infection Due to Streptococcus, Group B, Streptococcus Agalactiae

Start: 2016-03-29End: 2016-11-02Updated: 2024-04-04

Related Papers

Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial

Vaccine2020-09-0158 citations

Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4–6 Years After a First Dose: Results From a Phase 2 Trial

Clinical Infectious Diseases2019-08-0132 citations